Receive our newsletter – data, insights and analysis delivered to you
  1. Market Data
November 25, 2011

Sphere Medical’s Proxima blood analyser meets primary endpoint

Sphere Medical's Proxima Generation 2 has met its primary endpoint in a multicentre clinical trial conducted at two UK hospitals, Queen Elizabeth Hospital Birmingham and West Suffolk Hospital.

Sphere Medical’s Proxima Generation 2 has met its primary endpoint in a multicentre clinical trial conducted at two UK hospitals, Queen Elizabeth Hospital Birmingham and West Suffolk Hospital.

The Proxima system is an arterial blood analyser based on Sphere Medical’s proprietary microanalyser platform technology.

The primary endpoint of the study has evaluated the similar performance to laboratory and point-of-care blood-gas analysers, measuring arterial blood in a clinical setting.

The device provides real-time analysis of a patient’s arterial blood with laboratory accuracy.

Output data being displayed on a bedside monitor.

The company claims that the Proxima blood analyser can be useable for repeated blood measurements without a deterioration in performance.

Content from our partners
Why this global life sciences COO believes relocation to Charleston, SC, was key to achieving next-level success
The powerful networks advancing life sciences in Charleston | USA
The power of infrastructure: How Charleston | SC | USA is expanding horizons for life science companies

Sphere Medical CEO Stuart Hendry said the Proxima will deliver rapid and convenient measurement of blood chemistry in a critical care setting.

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Get important industry news and analysis sent to your inbox
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Hospital Management